MDWD vs SN.L
MDWD: MediWound develops enzymatic biotherapies that debride wounds and burns by removing dead tissue, targeting faster healing with biological precision. SN.L: A global medical technology leader focused on restoring patient mobility through advanced orthopedic, sports medicine, and wound care solutions.
Side-by-side fundamentals
| Metric | MDWD | SN.L | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $13.21 | £10.74 | |
| Market cap as of 2026-08-24 | $174M | n/a | |
| Net margin as of 2026-08-24 | -180.3% | n/a | |
| Gross margin as of 2026-08-24 | +19.6% | n/a | |
| Operating margin as of 2026-08-24 | -193.5% | n/a | |
| ROE as of 2026-08-24 | -67.2% | n/a | |
| ROA as of 2026-08-24 | -31.9% | n/a | |
| Debt / equity as of 2026-08-24 | 0.20 | n/a | |
| Revenue growth (YoY) as of 2026-08-24 | -24.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -13.8% | n/a | |
| Beta as of 2026-08-24 | 0.09 | n/a | |
| 1-year return as of 2026-08-21 close | -24.0% | -22.8% | SN.L higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.